Case studies

Better decisions, in real development programs

Anonymized results from sponsors who used PhaseV to prioritize assets, find the patients who respond, design stronger trials and choose the right sites.
How Smarter Site Selection Saved a Phase 3 Lung Cancer Trial 9 Months and $30M

How Smarter Site Selection Saved a Phase 3 Lung Cancer Trial 9 Months and $30M

A Phase 3 lung cancer trial was set to miss its 24-month goal. Smarter sites and design cut 9 months, 33 sites and 95 patients.
$30Mestimated cost saved
How Causal ML Site Selection Nearly Halved Enrollment Time in Two Global COPD Trials

How Causal ML Site Selection Nearly Halved Enrollment Time in Two Global COPD Trials

Two global Phase 3 COPD trials faced up to 3.8 years of enrollment. A causal ML site list cut the estimate to 1.95 years with 25 fewer sites.
1.95years to enroll, down from 3.8
How AI-Optimized Adaptive Design Cut a Phase 3 Infectious Disease Trial by 6 Months

How AI-Optimized Adaptive Design Cut a Phase 3 Infectious Disease Trial by 6 Months

Simulating millions of designs found a Phase 3 adaptive trial that is 25% shorter with 9% fewer patients, saving $6.05M at about 90% power.
25%shorter trial
How Adaptive Enrichment Gave a Phase 2 Rheumatic Disease Trial 25% More Statistical Power

How Adaptive Enrichment Gave a Phase 2 Rheumatic Disease Trial 25% More Statistical Power

Simulation designed a Phase 2 rheumatic disease trial that focuses enrollment on likely responders, with a 25% gain in statistical power.
25%more statistical power
Rescuing a Failed Phase III Trial: Finding the Patients Who Respond to Oral Insulin

Rescuing a Failed Phase III Trial: Finding the Patients Who Respond to Oral Insulin

After a Phase III oral insulin trial missed its endpoint, causal ML found the responder subgroups. Oramed re-initiated a Phase III trial.
How Finding the Right ALS Patients Led to a Smaller, Higher-Probability Phase 3 Trial

How Finding the Right ALS Patients Led to a Smaller, Higher-Probability Phase 3 Trial

A progression model and a high-efficacy subgroup informed a Phase 3 ALS design with a smaller sample size and a higher probability of success.
How a Lupus Prognostic Model Cut Variance 15% and Shrank the Next Trial

How a Lupus Prognostic Model Cut Variance 15% and Shrank the Next Trial

A lupus prognostic model cut variance by about 15%, equivalent to 92 fewer participants, and informed the client’s next trial design.
~15%variance reduction
How a Top-5 Pharma Company Valued a Biotech Pipeline in 8 Weeks

How a Top-5 Pharma Company Valued a Biotech Pipeline in 8 Weeks

A top-five pharma ranked a target biotech’s indications on causal evidence, market and feasibility in 8 weeks, saving over $1M in external spend.
8 wksto deliver insights
What Causal Analysis Revealed About Weight Loss and Obesity-Related Disease

What Causal Analysis Revealed About Weight Loss and Obesity-Related Disease

Causal analysis showed benefit appears only at very high weight loss and split weight-driven from direct drug effects.
ClinOps Optimizer
Portfolio Optimizer
Response Optimizer
Trial Optimizer
Hematology
Immunology
Infectious Disease
Metabolic
Nephrology
Neurology
Oncology
Pulmonology
Rare Disease